November 20, 2015
Clovis Oncology Inc.'s stock price plunged after the drugmaker revealed it gave the U.S. Food and Drug Administration immature clinical trial data when seeking approval for lung cancer drug rociletinib, according to proposed shareholder class actions filed Thursday and Friday.